In Vitro Tests To Predict The Reactogenicity Of Rna Therapy Drugs

Organisation / Company: Università degli studi di Messina Research Field: Medical sciences, Biological sciences, Pharmacological sciences Researcher Profile: Recognised Researcher (R2), Leading Researcher (R4), First Stage Researcher (R1), Established Researcher (R3) Country: Italy Application Deadline: 14 Jan 2025 - 12:00 (UTC) Type of Contract: To be defined Job Status: Not Applicable Funding: Not funded by a EU programme Research Infrastructure: No Offer Description: The described project focuses on one of the main obstacles to the development of RNA-therapy drugs, namely the innate immune response that recognizes these molecules as potential threats, triggering the production of type I interferons (IN I) and other pro-inflammatory cytokines. This response can cause severe side effects and reduce the drugs' efficacy. Therefore, there is an urgent need to develop methods that minimize these effects and provide a better understanding of the mechanisms underlying these reactions. The main objective of the project is to develop rapid human blood-based tests to predict the reactogenicity of experimental RNA-therapy drugs, enabling the selection of the safest drug candidates, hemodynamic, respiratory and metabolic function; metabolic assessment by microdialysis of donor organs undergoing reconditioning. Minimum Requirements: Master's / specialist / old system degree relating to the relevant scientific disciplinary area obtained in Italy or the equivalent qualification obtained abroad: Degree Course in Medicine and Surgery (LM41) Degree Course in Medical, Veterinary and Pharmaceutical Biotechnology (LM9) Bachelor's Degree in Chemical, Biological, Pharmaceutical and Environmental Sciences (LM6) Doctorate on subjects related to the topics of the research grant Eligibility of Fellows: EUROPE Nationality: EUROPE Selection Process: The selection process will focus on RNA-therapy drugs, nucleic acid recognition by the innate immune system, and immune sensors in adverse drug reactions in RNA-based therapeutics. Contact phone: 090 221 2252 - 090 221 3680 J-18808-Ljbffr

Location: lazio, IT

Posted Date: 1/12/2025